论文部分内容阅读
目的:观察吉西他滨+顺铂+地塞米松(GDP)方案治疗复发和难治性非霍奇金淋巴瘤(NHL)的疗效和不良反应。方法:回顾性分析用GDP方案治疗的26例复发和难治性非霍奇金淋巴瘤患者的临床资料,包括治疗后缓解情况以及出现的不良反应。结果:26例患者均可评价疗效和不良反应,其中完全缓解(CR)9例,部分缓解(PR)8例,稳定(SD)7例,进展(PD)2例,总有效率为65.4%。主要不良反应为消化道和骨髓抑制,对症治疗可恢复,无治疗相关死亡。结论:GDP方案治疗难治和复发性非霍奇金淋巴瘤疗效好,副作用可以耐受,安全性好,是一种值得进一步推广的挽救治疗方案。
Objective: To observe the efficacy and side effects of gemcitabine + cisplatin + dexamethasone (GDP) regimen in relapsed and refractory non-Hodgkin lymphoma (NHL). Methods: The clinical data of 26 patients with recurrent and refractory non-Hodgkin’s lymphoma treated with GDP regimen were retrospectively analyzed, including the post-treatment remission and the adverse reactions. Results: Efficacy and adverse reactions were evaluated in 26 patients. There were 9 patients with complete remission (CR), 8 with partial remission (PR), 7 with stable (SD) and 2 with progress (PD). The total effective rate was 65.4% . The main adverse reactions were gastrointestinal and bone marrow suppression, symptomatic treatment can be restored, no treatment-related deaths. Conclusion: The GDP regimen is effective in treating refractory and recurrent non-Hodgkin’s lymphoma. The side effects can be tolerated and the safety is good. It is a salvage and treatment plan worth further promotion.